XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
  Anti-Inflammatory
  Antivirals
  Antihypertensives
  Anticholesterol
  Anti-Clotting Drugs
  Anti Cancer Drugs
  Hypnotics
  PPI
  Antibiotics
  Analgesics
  Surfactants
  Fatty Acids
  Adrenergics
  Metals
  Varenicline
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Pharmacology Channel
subscribe to Pharmacology newsletter

Latest Research : Pharmacology

   DISCUSS   |   EMAIL   |   PRINT
October and November 2004 Lot of Neurontin Recalled
Apr 24, 2005, 07:53, Reviewed by: Dr.

Patients should not stop taking Neurontin before consulting with their physician. If they filled a prescription for the product in 100 mg strength between October 1, 2004 and March 15, 2005 and are concerned that any unused capsules may be part of the recalled lot, they should contact their pharmacist.

 
Pfizer Inc voluntarily recalled one lot (40,000 bottles) of 100 mg capsules of its epilepsy medication, Neurontin, after a manufacturing mechanical failure resulted in some bottles containing empty or partially filled capsules.

Pfizer said only 100 mg strength capsules from lot #15224V --distributed in October and November 2004 -- are included in the recall. The production lot was distributed only in the United States. No other Neurontin lots were affected.

The company said it is possible that patients taking Neurontin to control epilepsy could experience seizures from a missed dose of the product.

Although pharmacists and Pfizer distributors were notified on February 23 of the recall and pharmacists were instructed to immediately contact any of their customers using Neurontin, Pfizer wants to ensure full patient awareness.

The company has worked closely with the FDA throughout the recall process. Patients should not stop taking Neurontin before consulting with their physician. If they filled a prescription for the product in 100 mg strength between October 1, 2004 and March 15, 2005 and are concerned that any unused capsules may be part of the recalled lot, they should contact their pharmacist.

If consumers have questions about the recall, they should contact Pfizer Medical Information at 1-800-438-1985.

Pfizer said the recall of the affected lot will not result in a shortage of Neurontin 100 mg capsules.
 

- U.S. Food and Drug Administration (FDA)
 

www.pfizer.com

 
Subscribe to Pharmacology Newsletter
E-mail Address:

 

If consumers have questions about the recall, they should contact Pfizer Medical Information at 1-800-438-1985.

Related Pharmacology News

Phase Ib Trial Is Evaluating Bavituximab Administered With Common Chemotherapy Regimens
Two-component lantibiotic with therapeutic potential discovered
Prescription pain medication abuse on rise
Antibiotic inhibits cancer gene activity
NRTIs limits the atherogenic side effect of the protease inhibitors
Cyclin-dependent kinase inhibitors: The latest anti-inflammatory
FDA requested to promptly approve 17-P to prevent premature birth
Rapamycin shown to inhibit angiogenesis
Tigecycline, world�s first glycylcycline expanded broad-spectrum antibiotic, launched in UK
Ibuprofen - worsening cognitive function


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us